Inhibitor of antagonist binding to the muscarinic receptor is elevated in Alzheimer's brain (original) (raw)
Muscarinic receptors and novel strategies for the treatment of age-related brain disorders
William Roeske
Life Sciences, 1994
View PDFchevron_right
The Potential for Muscarinic Receptor Subtype-Specific Pharmacotherapy for Alzheimer's Disease
Joseph T Coyle
Mayo Clinic Proceedings, 1991
View PDFchevron_right
Endogenous Alzheimer's Brain Factor and Oxidized Glutathione Inhibit Antagonist Binding to the Muscarinic Receptor
John Frank
Brain research, 1996
View PDFchevron_right
M1 Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy
Abraham Fisher
Journal of Molecular Neuroscience, 2003
View PDFchevron_right
The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's disease
Marsha Tennis
Annals of Neurology, 2000
View PDFchevron_right
Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis
Abraham Fisher
Journal of Physiology-Paris, 1998
View PDFchevron_right
Variation of muscarinic activities of oxotremorine analogues
James Semple
Drug Development Research, 1988
View PDFchevron_right
Functional and direct binding studies using subtype selective muscarinic receptor antagonists
Roger Whiting
British Journal of Pharmacology, 1988
View PDFchevron_right
Pharmacological approaches to targeting muscarinic acetylcholine receptors
Ada M Tata
Recent patents on CNS drug discovery, 2014
View PDFchevron_right
High affinity acylating antagonists for muscarinic receptors
Naftali Malka
Life Sciences, 1992
View PDFchevron_right
Inactivation of brain cortex muscarinic receptors by 4-diphenylacetoxy-1-(2-chloroethyl) piperidine mustard
Magali Waelbroeck
Biochemical Pharmacology, 1992
View PDFchevron_right
Cholinergic Treatments With Emphasis on M1 Muscarinic Agonists As Potential Disease-Modifying Agents for Alzheimer's Disease
Abraham Fisher
Neurotherapeutics: the journal of the American Society …, 2008
View PDFchevron_right
Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists
Lucia Sue
Brain Research, 2001
View PDFchevron_right
Aprophit: An irreversible antagonist for muscarinic receptors
Peter Chiang
Biochemical Pharmacology, 1990
View PDFchevron_right
Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models
Manish Malviya
Neurochemistry International, 2008
View PDFchevron_right
Affinity of muscarinic receptor antagonists for three putative muscarinic receptor binding sites
Roger Whiting
British Journal of Pharmacology, 1989
View PDFchevron_right
Muscarinic receptor 1 agonist activity of novel arecoline derivatives in Alzheimer s presenile dementia models
Manish Malviya
2009
View PDFchevron_right
Rat brain and heart muscarinic receptors: Modification with tetranitromethane
David Gurwitz
Biochemical and Biophysical Research Communications, 1985
View PDFchevron_right
U-80816: A novel partial muscarinic agonist
Richard Heier
Drug Development Research, 1991
View PDFchevron_right
Novel long-acting antagonists of muscarinic ACh receptors
Vladimír Doležal
British Journal of Pharmacology
View PDFchevron_right
New functionally selective muscarinic agonists
Magali Waelbroeck
Life Sciences, 1993
View PDFchevron_right
Tertiary (2-haloethyl)amine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride
Frederick Ehlert
Journal of Medicinal Chemistry, 1990
View PDFchevron_right
Selective Signaling via Unique Ml Muscarinic Agonistsa
Daniele Marciano
Annals of the New York Academy of Sciences, 1993
View PDFchevron_right
Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients 2003
Abdu Adem
View PDFchevron_right
Antagonist binding profiles of five cloned human muscarinic receptor subtypes
Frank Dörje
The Journal of pharmacology and experimental therapeutics, 1991
View PDFchevron_right
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations
Frank Dörje
British Journal of Pharmacology, 1991
View PDFchevron_right
Agonist and Antagonist Binding of Muscarinic Acetylcholine Receptors Purified from Porcine Brain: Interconversion of High- and Low-Affinity Sites by Sulfhydryl Reagents
T. Haga
Journal of Neurochemistry, 1988
View PDFchevron_right
Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System
Christian Felder
Journal of Medicinal Chemistry, 2000
View PDFchevron_right
Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid β1–42
Vladimír Doležal
Neuropharmacology, 2013
View PDFchevron_right
Benzylidene ketal derivatives as M2 muscarinic receptor antagonists
Vicki COFFIN
Bioorganic & Medicinal Chemistry Letters, 2000
View PDFchevron_right
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer’s presenile dementia models
Manish Malviya
Bioorganic & Medicinal Chemistry, 2009
View PDFchevron_right
Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex
Agneta Nordberg
Journal of Neural Transmission, 1988
View PDFchevron_right
Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia
Jeffrey Conn
Neuropsychiatric Disease and Treatment, 2014
View PDFchevron_right
Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives
Piero Angeli, Fulvio Gualtieri
Biochemical Pharmacology, 2005
View PDFchevron_right